natgillin/translations-raw huggingface dataset:
A compound according to claim 1 wherein: is selected from —CN, —OCF3, —CF3, —Cl, —Br and phenyl, pyrimidinyl and triazolyl, wherein said phenyl ring is optionally substituted with —F; 
Spoj prema zahtjevu 1, naznačen time, da: R' je odabran od sljedećih: -CN, -OCF:,-CF, -C1, -Br i fenil, pirimidinil i triazolil, gdje navedeni fenilni prstenje opcijski supstituiran s -F;
2G, Hydrolysis of Peak 2 to give Isomer D 20% aqueous sodium hydroxide solution (53 ml) was added to a stirred solution of Mosher's ester peak 2 (2.42 g, 4.52 mmol) in methanol (158 ml) and the mixture stirred at reflux for 150 minutes. 
Hidroliza Peak-a 2 da bi se dobio Izomer D (nije spoj izuma) 20%-tna vodena otopina natrij hidroksida (53 ml) se doda u miješanu otopinu Mosher-ovog estera peak-a 2 (2.42 g, 4.52 mmol) u metanolu (158 ml) i smjesa se miješa uz refluks tijekom 150 minuta.
A process for producing, on an industrial scale, capsular polysaccharide of Haemophilus influenzae type b (PRP) suitable for use in a vaccine, the process comprising culturing a strain of Haemophilus influenzae type b (Hib) in a culture medium, and harvesting and treating supernatant from the culture medium to extract the capsular polysaccharide therefrom, said culture medium comprising at least: 
PATENTNI ZAHTJEVI Postupak za proizvodnju, na industrijskoj razini, kapsularnog polisaharida Haemophilus influenzae tipa b (PRP) namijenjenog za potrebe cjepiva, prema kojem se soj Haemophilus influenzae tipa b (Hib) kultivira u mediju za kultiviranje, a supernatant kulture se sakuplja 1 obrađuje kako bi se iz njega ekstrahirao kapsularni polisaharid, te navedeni medij za kultiviranje sadrži barem:
A compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof. 
HR P20151368 T1 PATENTNI ZAHTJEVI no Spoj predstavljen slijedećom strukturnom formulom:
Structure in accordance with claim 14, in which said elements of the insulating surround are interconnected with a geometrical or joint coupling. 
Struktura prema zahtjevu 13, naznačena time da su navedeni elementi (12’,12a,12b) izolacijskog okruženja (12) međusobno povezani geometrijskim spojem ili spojkom.
A process according to claim 7 or claim 8 wherein the said temperature difference is up to 50°C. 
Postupak u skladu s patentnim zahtjevom 7 ili 8 pri čemu je navedena razlika temperatura do 50%C.
The bacterium of claim 3, wherein the sacB gene is operably linked to a promoter comprising the sequence as set forth in SEQ ID NO:5. 
Soj bakterije domaćina prema bilo kojem od zahtjeva 1 do 5, naznačen time, da bakterijski soj sadrži jednu ili više kopija polinukleotida koji sadrži sekvencu kao što je prikazana u SEQ ID NO:75.
A toothbrush (10) according to claim 12 in which the follower comprises a bushing surrounding the cam. 
Četkica za zube (10) sukladno zahtjevu 12 pri čemu slijednik sadrži utičnicu koja okružuje ekscentar.
a first encoder to LDPC encode Layer 1 signaling data to generate LDPC parity bits; 
LDPC dekodiranje signalnih podataka LI i zatvorenih LDPC paritetnih bitova; 1
85 % of ropinirole released by 12 hours; and at least 70 % of ropinirole released by 20 hours. 
55 do 85 % ropinirola se oslobađa za 12 sati; i najmanje 70% ropinirola se oslobađa za 20 sati.
Use according to claim 26, wherein said anxiety disorders are selected from the group consisting of anxiety and disorders and diseases related to panic attack, agoraphobia, panic disorder with agoraphobia, panic disorder without agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia and other specific phobias, obsessive-compulsive disorder, post-traumatic stress disorder, acute stress disorders, generalized anxiety disorder, anxiety disorder due to general medical condition, substance-induced anxiety disorder, separation anxiety disorder, adjustment disorders, performance anxiety, hypochondriacal disorders, anxiety disorder due to general medical condition and substance-induced anxiety disorder, and anxiety disorder not otherwise specified. 
Primjena prema patentnom zahtjevu 22, naznačena time što su navedeni anksiozni poremećaji izabrani iz grupe koju čine anksioznost i poremećaji i bolesti povezani sa paničnim napadom, agorafobija, panični poremećaj sa agorafobijom, panični poremećaj bez agorafobije, agorafobija bez povijesti paničnih napada, specifična fobija, socijalna fobija i druge specifične fobije, opsesivno-kompulzivni poremećaj, post-traumatski stresni poremećaj, akutni stresni poremećaji, generalizirani anksiozni poremećaj, anksiozni poremećaj kao posljedica općeg medicinskog stanja, anksiozni poremećaj izazvan supstancom, anksiozni poremećaj odvajanja u djetinjstvu, poremećaji prilagođavanja, anksioznost pri javnom nastupu, hipohondrijski poremećaji, anksiozni poremećaj kao posljedica općeg medicinskog stanja i anksiozni poremećaj izazvan supstancom, i anksiozni poremećaj koji nije drugačije naznačen.
The crystallized material may further be disaggregated or screened to remove clusters of micro crystals. 
Kristalizirani materijal može nadalje biti razlomljen ili prosijan da bi se uklonile nakupine mikrokristala.
An isolated nucleic acid molecule encoding the antibody of claim 1. 
Izolirana molekula nukleinske kiseline, naznačena time, što kodira antitijelo ili njegov antigen-vežući fragment iz zahtjeva 1.
from 1 to 10 single amino acid alterations compared to SEQ ID NOs: 77 to 95; 
(b) od 1 do 10 pojedinačnih izmjena amino kiselina u usporedbi sa SEQ ID Br.
A liquid long acting injectable formulation for use according to claim 10, wherein the endoparasite is an anthelminth selected from the group consisting of Ancylostoma, Anecator, Ascaris, Capillaria, Cooperia, Dirofilaria, Dictyocaulus, Echinococcus, Fasciola, Haemonchus, Oesophagostomum, Ostertagia, Toxocara, Strongy hides, Toxascaris, Trichinella, Trichuris, Trichostrongylus and mixtures thereof. 
Tekuća imjektibilna formulacija s produljenim djelovanjem za uporabu prema zahtjevu 8, naznačena time, da endoparazit je helmint odabran iz skupine koju čine: Ancylostoma, Anecator, Ascaris, Capillaria, Cooperia, Dirofilaria, Dictyocaulus, Echinococcus, Fasciola, Haemonchus, Oesophagostomum, Ostertagia, Toxocara, Strongyloides, Toxascaris, Trichinella, Trichuris, Trichostrongylus i njihove kombinacije.
A protein layer according to claim 1, wherein the second oligomer assembly belongs to a dihedral point group of order 2 or to a cyclic point group of order 2. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time, da drugi skup oligomera pripada dihedralnoj točkinoj grupi reda 2 ili cikličkoj točkinoj grupi reda 2.
The C1-INH for use according to claim 1, wherein the long lasting therapeutic effect remains effective greater than 3 months after cessation of therapy. 
C1-INH namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što postupak rezultira terapijskim učinkom koji traje najmanje 3 mjeseca nakon prekida terapije.
A cylinder lock as defined in claim 26, wherein said body part (217) is guided for limited rotational movement, said projecting lugs (220a, 221a) being adapted for possible sliding engagement with a longitudinal code pattern (125) disposed on at least one side of an associated key (122). 
Cilindar brava kako je definirano u zahtjevu 26, naznačena time da je navedeni dio kučišta (217) voden radi ograničenog rotacijskog kretanja, a navedene izbočene stopice (220a, 221a) su prilagođene radi mogućeg kliznog međudjelovanja sa uzdužnim kodnim uzorkom (125) raspoređenim na barem jednoj strani pripadajućeg ključa
The immunogenic composition of claims 1-18 or the vaccine of claim 19 for use according to claim 21 wherein the disease is: either or both of pneumonia or invasive pneumococcal disease (IPD) of elderly humans, exacerbations of chronic obstructive pulmonary disease (COPD) of elderly humans, otitis media of infant humans, meningitis and/or bacteraemia of infant humans, or pneumonia and/or conjunctivitis of infant humans. 
Imunogeni pripravak u skladu s patentnim zahtjevima 1-9 ili cjepivo u skladu s patentnim zahtjevom 10, naznačeni time što su namijenjeni upotrebi u liječenju ili sprječavanju bolesti uzrokovane infekcijom bakterijom Streptococcus pneumonijae u skladu s patentnim zahtjevom 12, gdje je bolest bilo pneumonija ili/i invazivna pneumokokna bolest (IPD) kod starijih ljudi, egzacerbacije kronična opstruktivne plućne bolesti (COPD) kod starijih ljudi, upala srednjeg uha kod ljudske dojenčadi, meningitis i/ili bakteriemija kod ljudske dojenčadi, ili pneumonija i/ili konjunktivitis kod ljudske dojenčadi.
The process of paragraph 47, wherein said second base is selected from the group consisting of triethylamine; 1,5-diazabicyclo[4,3,0]non-5-ene 1,4-diazabicyclo[2,2,2]octane; 1,8-diazabicyclo[5,4,0]undec-7-ene; and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 37, naznačen time što navedenu drugu bazu se bira iz skupine koju čine trietilamin; 1,5-diazabiciklo[4.3.0]non-5-en; 1,4-diazabiciklo[2.2.2]oktan; 1,8-diazabiciklo[5.4.Ojundec-7-en; i smjese 2 ili više njih.
The compound for use according to claim 1, wherein R1, R2, and R3 are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkynyl, cyano, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, nitro, NRARB, and (NRARB)carbonyl; 
Ri, R2, i Rs su neovisno odabrani iz skupine koja se sastoji od vodika, alkenila, alkoksi, alkoksikarbonila, alkila, alkinila, cijano, haloalkoksi, haloalkila, halogena, hidroksi, hidroksialkila, nitro, NR,R; i (NRaRe)karbonila; HR P20130861 T1 Jo ne
The method of Claim 1 or Claim 2, wherein said at least a portion of said CRISPR locus of said parent bacterial strain and at least a portion of said modified CRISPR locus of said bacteriophage resistant variant strain are compared by sequencing at least a portion of said CRISPR locus and at least a portion of said modified CRISPR locus. 
Postupak prema zahtjevu 1, naznačen time da se navedeni barem dio navedenog CRISPR lokusa navedenog matičnog bakterijskog soja i barem dio navedenog modificiranog CRISPR lokusa navedenih varijanti sojeva rezistentnih na bakteriofage uspoređuju sekvenciranjem barem dijela navedenog CRISPR lokusa i barem dijela navedenog modificiranog CRISPR lokusa.
A compound of claim 20, wherein m is 1 and R3 is selected from the group consisting of hydroxy, hydroxymethyl, amino, acylamino, acetylamino and methylamino. 
A (Rom (Rom pri čemu m je 1 i Rs je izabran iz skupine koju čine hidroksi, hidroksimetil, amino, acilamino, acetilamino i metilamino.
at least one dye as an aversive agent, 
(e) barem jednu boju kao averzivno sredstvo,
The edging strip as claimed in claim 1, characterized in that the copolymers of propylene are copolymers of polypropylene and polyethylene. The edging strip as claimed in claim 1, characterized in that the modulus of elasticity of the melt layer is no more than 1400 MPa. 
Rubna traka prema jednom od prethodnih zahtjeva, naznačen time, što je modul elastičnosti sloja taljevine 1400 MPa ili manje, poželjno 1200 MPa ili manje; i/ili što je temperatura taljenja 160°C ili manje, poželjno 150 °C.
The results of the process steps explained above could be seen in FIG. 2 c as the grooves 6 ′ which are introduced there and which produce the groove structure 4 from the underside of the lower part 2, and which thus ultimately make the nozzle channel 5 ′ in the upper part accessible. 
Gore objašnjeni rezultati ovog koraka postupka mogu se vidjeti na slici 2c kao brazde 6' koje su tamo uvedene i koje stvaraju brazdastu strukturu 4 s donje strane donjeg dijela 2, i koje time tvore raspoloživi kanal mlaznice 5' u gornjem dijelu.
A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of any one of claims 1 to 10, and optionally further comprising one or more other suitable therapeutic agents selected from: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, anti-pancreatic agents, lipid lowering agents, anorectic agents, and appetite suppressants. 
Farmaceutska kompozicija, koja sadrži farmaceutski prihvatljiv nosač i spoj bilo kojeg od patentnih zahtjeva 1 do 10, i opcionalno koja dalje sadrži jedan ili više drugih pogodnih terapijskih agenasa odabranih od: anti-dijabetesni agensi, anti-hiperglikemijski agensi, anti-hiperinsulinemijski agensi, agensi protiv retinopatije, anti-neuropatični agensi, anti-nefropatični agensi, anti-aterosklerotični agensi, anti-ishemijski agensi, anti-hipertenzivni agensi, agensi protiv gojaznosti, anti-dislipidemijski agensi, anti-hiperlipidemijski agensi, anti-hipertrigliceridemijski agensi, anti-hiperkolesterolemijski agensi, agensi protiv restenoze, agensi protiv oboljenja gušterače, agensi za snižavanje lipida, agensi sa anoreksičnim djelovanjem, i supresori apetita.
The formation of donepezil hydrochloride hydrate form I or form IV depends upon the water content in the solvent mixture. 
Nastajanje donepezil hidroklorida hidratnog oblika I ili oblika IV ovisi o količini vode u otapajućoj smjesi.
A cytotoxic compound comprising a linking group with a reactive group bonded thereto capable of covalently linking the cytotoxic compound to a cell binding agent (CBA), wherein said cytotoxic compound is represented by the following formula: or a pharmaceutically acceptable salt thereof, wherein: 
, ili njihovom farmaceutski prihvatljivom soli, pri čemu je modificirani citotoksični spoj proizveden reagiranjem citotoksičnog spoja koji sadrži imin koji nosi tiol skupinu s imin reaktivnim reagensom i pri čemu je citotoksični spoj koji sadrži imin predstavljen jednom od sljedećih formula:
The cake is washed with 2L/kg of methanol. 
Masa se ispire s 2L/kg metanola.
A bilirubin particle having a size of 1-1,000 nm formed by self-assembling of a composite containing bilirubin and a hydrophilic polymer bound to the bilirubin, wherein the hydrophilic polymer is bound to a carboxyl group of the bilirubin. 
Čestica bilirubina veličine 1-1,000 nm dobivena je samosastavljanjem kompozita koji sadrži bilirubin i hidrofilni polimer vezan na bilirubin, naznačen time što je hidrofilni polimer vezan na karboksilnu skupinu bilirubina.
allowing the thus obtained composition or concentrated multi-component to cool down and packaging it. 
€) omogućavanje ovako dobivenoj kompoziciji ili koncentriranoj multikomponenti da se ohladi, i pakiranje iste.
Pharmacokinetics of the Compound ST1469 and its Corresponding Des Methyl Derivative ST2087 
Farmakokinetika spoja ST1469 1 njegov odgovarajući des metil derivat ST2087.
The method as claimed in claim 1, wherein the zeolite is loaded with the metals by means of ion exchange. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se zeolit puni metalima izmjenom iona.
The compound or a pharmaceutically acceptable salt thereof for use according to claim 17 or 18, wherein said AB-related pathology is Alzheimer's disease. 
Spoj ili njegova farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 4, naznačen time da navedena AB-povezana patologija je Alzheimerova bolest.
to react in the presence of a compound of formula R1SR2 and a chlorine-containing reagent under conditions sufficient to make the compound of formula (II), wherein: 
(D da reagira u prisutnosti smjese spoja formule R,SR> i trikloroizocijanurne kiseline, pod uvjetima koji su dovoljni da se pripravi spoj formule (II):
automatic control of the flight of kites 2; 
Datum objave europske prijave patenta:
The polyvinylidene chloride copolymers used in the present invention can be any of the following, polyvinylidene chloride-co-, acrylic acid, methyl acrylic acid, vinyl chloride, vinyl acetate, methyl methacrylate, propylene, ethylene, acrylates, styrene's, or any combination of the above mention monomers which form the copolymer composition. 
Poliviniliden klorid kopolimeri korišteni u predstavljenom izumu mogu biti bilo koji od sljedećih, poliviniliden klorid- ko-, akrilna kiselina, metil akrilna kiselina, vinil klorid, vinil acetat, metil metakrilat, propilen, etilen, akrilati, stireni, ili bilo koja kombinacija prethodno navedenih monomera koji formiraju kopolimernu kompoziciju.
Subsequently, the obtained veneer can be applied by gluing onto a substrate, such as a particle board. 
Nakon toga se dobiveni furnir može staviti uz primjenu lijepljenja na podlogu, takvu kao stoje iverica.
is 7 amino acid residues in length; and 
L; je duljine 7 ostataka amino kiseline;
The method of claim 11, wherein the continuous cultivation of mammalian cells is performed in perfusion mode. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time što se kontinuirani uzgoj stanica:
An airflow adaptor according to claim 4 wherein the ratio of the sum of the cross-sectional areas of the second apertures in the second circumferential flange to the cross-sectional area of the first conduit is such that when a pressure breath induced low pressure is applied to the distal end of the airflow adaptor at least 5% of the resulting airflow is through the second apertures. A deagglomerator for a breath-actuated dry powder inhaler, the deagglomerator comprising an airflow adaptor according to claim 1 . 
Inhalator prema zahtjevu 4 gdje je omjer zbroja poprečnih presjeka otvora u drugoj obodnoj prirubnici (208; 308; 508; 705) prema poprečnom presjeku prve cijevi (101; 202; 302; 507; 602; 703) takav da kada se disanjem nastali niski tlak primijeni na distalni kraj adaptora protoka zraka (101; 202; 302; 507; 602; 703) barem 20% nastalog protoka zraka bude kroz otvore.
The tablet of any one of embodiments 1-10 wherein the first layer comprises a basifying agent. The tablet of embodiment 11 wherein the basifying agent is selected from croscarmellose sodium, calcium carbonate, sodium hydroxide, aluminum oxide, alkali metal hydroxides,alkaline earth metal hydroxides, aluminum hydroxide, dihydroaluminum, sodium carbonate, ammonium hydroxides, magnesium carbonate, magnesium stearate, piperazine, sodium acetate, sodium citrate, sodium tartrate, sodium maleate, and sodium succinate and mixtures thereof. 
Tableta bilo kojeg od zahtjeva 1-7 gdje prvi sloj sadrži sredstvo za povećanje baznosti koje je prvenstveno izabrano od kroskarmeloza-natrija, kalcijevog karbonata, natrijevog hidroksida, aluminijevog oksida, hidroksida alkalnih metala, hidroksida zemnoalkalnih metala, aluminijevog hidroksida, dihidroaluminija, natrijevog karbonata, amonijevog hidroksida, magnezijevog karbonata, magnezijevog stearata, piperazina, natrijevog acetata, natrijevog citrata, natrijevog tartarata, natrijevog maleata, i natrijevog sukcinata i njihovih mikstura.
The method of claim 1, wherein the antibody, or antigen-binding portion thereof, exhibits one or a combination of the following properties: 
Antitijelo, ili njegov antigen-vezujući dio, bilo kojeg od prethodnih patentnih zahtjeva, koji pokazuje jednu ili kombinaciju sljedećih svojstava:
The inner boot according to one or more of the preceding claims, characterized in that said bellows band (14) is made of plastic material. 
Unutarnja čizma prema jednom ili više prethodnih zahtjeva, naznačena time, da je spomenuta rastezna traka (14) izrađena od plastičnog materijala.
The hybrid formulation according to claim 1 or 2, characterized in that the functionalized poly(dimethylsiloxane)-terminated vinyl is present in the formulation in an amount ranging from 2% to 5% by weight. 
Hibridna formulacija prema patentnom zahtjevu 1 ili 2, naznačena time, da funkcionalizirani poli(dimetilsiloksan) s vinilom na kraju jest prisutan u formulaciji u području od 2 tež.% do 5 tež.%.
said element made of perfumed plastic (20) comprises a hooking wall (23) which extends orthogonally with respect to said front wall (21) and carries a hooking seat (22) which is "C"-shaped; 
navedeni element načinjen od parfimirane plastike (20) sadrži stijenku za sidrenje (23), koja se pruža pod pravim kutem u odnosu na navedenu prednju stijenku (21) i nosi sijelo za sidrenje (22) u obliku slova "C";
A process according to claim 4, wherein said anhydrous halogenhydric acid is anhydrous hydrochloric acid generated in situ by reacting lithium chloride with methanesulfonic acid in the presence of tetrahydrofuran. 
Postupak prema zahtjevu 4 gdje je bezvodna halogenvodična kiselina bezvodna klorovodična kiselina dobivena in situ reakcijom litij klorida s metansulfonskom kiselinom u prisutnosti THF-a.
The composition of any one of claims 7 to 19, wherein the optional separating layer has a thickness of 20 µm to 120 µm. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da opcijski sloj za odvajanje ima debljinu od 20 um do 120 um.
The method of E 37, wherein the antagonist is a humanized monoclonal antibody or a fully human monoclonal antibody. 
Antagonist za uporabu u skladu sa zahtjevom 37, naznačen time, da antagonist je humanizirano monoklonsko antitijelo ili potpuno ljudsko monoklonsko antitijelo.
The method according to any one of the preceding claims, characterized in that the surface reacted calcium carbonate is in the form of granules having a specific surface area of from 1 to 175 m2/g, preferably of from 2 to 145 m2/g, more preferably 10 to 100 m2/g, especially preferably of from 20 to 70 m2/g, most preferably of from 30 to 40 m2/g, measured using nitrogen and the BET method according to ISO 9277. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da je površinski reagirani kalcijev karbonat u obliku granula koje imaju specifičnu površinu od 1 do 175 m'/g, poželjno od 2 do 145 m'/g, poželjnije 10 do 100 m'/g, naročito poželjno od 20 do 70 m//g, najpoželjnije od 30 do 40 m?/g, mjereno pomoću dušika i BET postupkom prema ISO 9277.
The composition in accordance with the present invention is applied as a film or as a thin layer on the nail surface in order to prevent and/or treat onychoschizia, which is a specific alteration of the ungual structure characterized by splitting of the two laminae of the nail plate. 
Pripravak koji se koristi u ovom izumu nanosi se kao film ili kao tanki sloj na površinu nokta kako bi se spriječile i/ili liječile specifične promjene ungualne strukture, poput smanjene snage, listanja noktiju i ungualne krhkosti.
The process according to any one of claims 1 to 27, characterized in that the at least one calcium carbonate material is provided as an aqueous suspension comprising from 1 wt% to 82 wt%, preferably from 15 wt% to 81 wt%, and most preferably from 40 wt% to 80 wt% of dry GCC and/or PCC, and in particular from 63 wt% to 72 wt% of dry GCC, and/or 47 wt% to 72 wt% of dry PCC. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 21, b da barem jedan materijal kalcijevog karbonata omogućen kao vodena otopina obuhvaća od 1 wt% do 82 wt%, poželjno od 15 wt% do 81 wt%, najpoželjnije od 40 wt% do 80 wt% suhog GCC i/ili PCC, a posebno od 63 wt% do 72 wt% suhog GCC i/ili 47 wt% do 72 wt% suhog PCC.
The output of each microprocessor 6a, 6b is connected to respective control stage 3a, 3b over a serial transmission channel 10a, 10b. 
Izlaz svakog mikroprocesora 6a, 6b je povezan s odnosnim upravljačkim podsklopom 3a, 3b preko serijskog prijenosnog kanala 10a, 10b.
As mentioned previously, motor 42 would present voltage readings that can be correlated with a varying amount of throughput of fluid through conduit 14. 
Kao što je naprijed rečeno, motor 42 ima napon koji se može povezati s promjenjivim protokom fluida kroz cjevovod 14.
receiving data from the sensor; 
primanje podataka s timera (248);
-14,13 °C Standard deviation 
-14.13 *C Standardna devijacija